Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lenalidomide + Rituximab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). | |
Rituximab | Rituxan | IDEC-C2B8|MabThera | CD20 Antibody 24 | Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 loss | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | Lenalidomide + Rituximab | Guideline | Actionable | Revlimid (lenalidomide) combined with Rituxan (rituximab) is indicated in the guidelines as second line and subsequent therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org). | detail... |
TP53 mutant | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | Lenalidomide + Rituximab | Guideline | Actionable | Revlimid (lenalidomide) combined with Rituxan (rituximab) is indicated in the guidelines as second line and subsequent therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05848765 | Phase II | Bendamustine + Obinutuzumab Epcoritamab-bysp + Lenalidomide Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Lenalidomide + Rituximab | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT) | Recruiting | GBR | 0 |
NCT06149286 | Phase III | Lenalidomide + Rituximab Lenalidomide + Odronextamab | A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | BEL | AUT | AUS | 4 |
NCT06084936 | Phase III | Obinutuzumab Glofitamab-gxbm Lenalidomide + Rituximab Bendamustine + Rituximab | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE) | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | CAN | BRA | AUS | 3 |
NCT06191744 | Phase III | Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Obinutuzumab Lenalidomide + Rituximab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NZL | NLD | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | BGR | BEL | AUS | 8 |
NCT05371093 | Phase III | axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT06006117 | Phase III | Lenalidomide + Rituximab Lenalidomide + Mosunetuzumab-axgb Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | Recruiting | FRA | 0 |
NCT05100862 | Phase III | Rituximab + Zanubrutinib Lenalidomide + Rituximab Obinutuzumab + Zanubrutinib | A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT02600897 | Phase Ib/II | Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | GBR | ESP | 0 |
NCT04680052 | Phase III | Lenalidomide + Rituximab Lenalidomide + Rituximab + Tafasitamab-cxix | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 5 |
NCT05888493 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tisagenlecleucel Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Lenalidomide + Rituximab | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA) | Recruiting | SVK | ROU | POL | HUN | ESP | CZE | AUS | 3 |
NCT04113226 | Phase II | Rituximab Lenalidomide + Rituximab | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage) | Recruiting | FRA | 0 |
NCT05409066 | Phase III | Lenalidomide + Rituximab Epcoritamab-bysp + Lenalidomide + Rituximab | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | Recruiting | USA | TUR | SWE | SVK | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT04224493 | Phase III | Lenalidomide + Rituximab + Tazemetostat Lenalidomide + Rituximab | Study in Subjects With Relapsed/Refractory Follicular Lymphoma | Recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT04404283 | Phase III | Lenalidomide + Rituximab Brentuximab vedotin + Lenalidomide + Rituximab | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUS | 2 |